Stockscreener 앱 받기
1.17
1.69%
-0.0201
시장 영업 전:
1.17
전일 마감가:
$1.1901
열려 있는:
$1.21
하루 거래량:
8,584
Relative Volume:
0.12
시가총액:
$6.90M
수익:
-
순이익/손실:
$-13.32M
주가수익비율:
-0.2665
EPS:
-4.39
순현금흐름:
$-13.01M
1주 성능:
+0.86%
1개월 성능:
+9.35%
6개월 성능:
-34.82%
1년 성능:
-40.91%
1일 변동 폭
$1.155
$1.21
1주일 범위
$1.115
$1.2408
52주 변동 폭
$0.925
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
PSTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
1.17 | 6.90M | 0 | -13.32M | -13.01M | -4.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Leptomeningeal Metastases Pipeline Analysis, Clinical - openPR
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight - The Globe and Mail
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA - openPR
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, - openPR
Stevanato Group (NYSE:STVN) & Plus Therapeutics (NASDAQ:PSTV) Head to Head Review - Defense World
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire
Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan
PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - STAT
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire
Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics - STAT
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire
Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan
Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire
Plus Therapeutics Secures 5-Year Supply Deal for Key Cancer Treatment Radioisotope - StockTitan
HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World
Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com
CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network
Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan
PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan
PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
Plus Therapeutics to Present Positive FORESEE Clinical - GlobeNewswire
Plus Therapeutics' CNSide Trial Shows 90% Success in Cancer Treatment Decisions | PSTV Stock News - StockTitan
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases - Yahoo Finance
Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire
Plus Therapeutics Reveals Breakthrough LM Cancer Biomarker Study with 88% Detection Rate | PSTV Stock News - StockTitan
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com
Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Plus: Q3 Earnings Snapshot - New Haven Register
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Plus Therapeutics Advances Cancer Drug Pipeline, Reports $4.4M Grant Revenue in Q3 | PSTV Stock News - StockTitan
Roche teams up with transcription factor trailblazer Flare in new $1.8B-plus cancer pact - Fierce Biotech
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India
Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire
Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire
Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan
Plus Therapeutics granted extension by Nasdaq - Investing.com
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):